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The Origin and Understanding of the
Incretin Concept
Jens F. Rehfeld*
Department of Clinical Biochemistry, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
Gastrointestinal hormones that stimulate insulin secretion at physiological concentrations
are incretins. This concept has recently attracted considerable attention in the wake of
drugs developed from the gut hormone GLP-1 (glucagon-like peptide-1) for diabetes
therapy. But the renewed enthusiasm has also restricted the concept to just two
hormones, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The purpose
of the present overview is two-fold: First to tell that the incretin concept is far from new.
It has a more than a century long history full of ups and downs. Second, that the incretin
concept may now have become too narrow. Thus, it is likely that incretin comprises
additional gastrointestinal hormones, which interact with GIP and GLP-1 during normal
meals containing protein, fat and complex carbohydrates (and not just pure glucose).
Such broader incretin concept may stimulate development of novel gut hormone-derived
drugs.
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INTRODUCTION
In gastrointestinal endocrinology, the concept of incretin is today highly topical and generally
applied to two distinct gut hormones with technical acronymous names: GIP (originally “gastric
inhibitory polypeptide,” later renamed “glucose-dependent insulinotropic polypeptide”) and GLP-1
[“glucagon-like peptide 1,” now in its truncated (7–36) form]. Of course it is more idiomatic to
use the single word “incretin” instead of two acronyms. Moreover, many younger scientists and
physicians today consider incretin a rather novel and fashionable concept surfacing in the wake of
the development of GLP-1-derived drugs for treatment of type 2 diabetes mellitus, a view furthered
by the growing business for the diabetes-related pharma industry. In other words, there is at
present a marked focus on the two above-mentioned hormones in gastrointestinal endocrinology.
To this end, there are also articles which are ostensibly dealing with gut hormones but mainly
report about GLP-1 and/or GIP, sometimes accompanied by measurements of a third gut hormone,
PYY (“peptide tyrosyl-tyrosyl”), or measurements of ghrelin [see for instance (1–4)]. These articles
contribute to the picture that gastrointestinal endocrinology today is essentially about GIP and
GLP-1.
It is exciting that gut hormones are now used as targets for development of drugs for major
diseases with large numbers of patients. But this is in fact what has been attempted for more
than a century. Likewise, the incretin concept as such is in some respects more than 140 years
old. But with the present conceptualization to just two hormones, incretin may lose aspects of
its meaning and understanding of what gastrointestinal endocrinology is fundamentally about.
Equally unfortunate, initiatives to develop additional relevant drugs may also be lost with today’s
narrow view on incretin.
Rehfeld The Incretin Concept
In this situation, a review on the origin and early phases of
gastrointestinal endocrinology leading to the incretin concept
may be pertinent. The report here may hopefully also pave the
way for a fuller and more relevant understanding of the biology
of gut hormones, and at the same time give due credit to pioneers
in the incretin story.
DEFINITION OF INCRETIN
Incretin is a word and concept constructed for a gut hormonal
factor assumed to supplement secretin in the effect on pancreatic
secretion. Thus, while secretin stimulates the secretion of water
and bicarbonate from the exocrine pancreatic cells (5, 6), it
has been suggested from the beginning that (an) other gut
hormone(s) would stimulate the internal or endocrine secretion
from pancreatic islet-cells (6, 7). Literally, it was the Belgian
physiologist Jean La Barre who coined the word “incrétine”
in 1932 (8). Consequently, the original definition suggests that
any gut hormone which under physiological circumstances
stimulates or contributes to the stimulation of the secretion
of pancreatic hormones [insulin, glucagon, PP (pancreatic
polypeptide), and pancreatic somatostatin] is an incretin.
The physiological context is of course important. Since the
function of hormones in the digestive tract fundamentally is to
facilitate digestion and subsequent absorption and metabolism
of food elements, the incretin activity is linked to the
gastrointestinal processing of ordinary meals. Hence, the original
incretin definition challenges unphysiological loadings, such as
intake of large amounts of for instance pure glucose or other pure
chemicals.
THE HISTORY OF INCRETIN
1850–1900: The mental framework for the idea of incretin
dates back to the second half of the nineteenth century, where
European physiologists began to focus on the mechanisms of the
external and internal secretion of the pancreas (5, 9–13). It was in
this period that Mering andMinkowski showed that the pancreas
was the site of origin for diabetes mellitus (14), and where Claude
Bernard tried to explain the fact that significantly larger amounts
of glucose can be given orally than intravenously without
glucosuria. Hence, Claude Bernard suggested that the liver takes
up most of the oral glucose during the first portal circulation
in order to prevent hyperglycemia (15). This explanation had
supporters up to the 1950’s (16).
1900–1960: A decisive breakthrough came in 1902, with
Bayliss’ and Starling’s hallmark discovery of secretin (5, 6)
that founded not only gastrointestinal endocrinology, but also
endocrinology in general. The discovery of secretin was also the
background for Starling’s Croonian lecture from 1905 (6), in
which he coined the word hormone (from Greek “hormoa”: I
arouse to activity). According to Moore et al. (7), the discovery
of the first hormone, secretin, also led Starling to suggest the
possibility that the duodenal mucosa in addition to secretin
produces another hormone that stimulates the internal secretion
of the pancreas. Moore et al. immediately tested Starling’s
hypothesis by oral administration of extracts of duodenal
mucosa to three recently diagnosed diabetes patients (7). In
hindsight, the results of such oral intake were of course negative
and inconclusive, because protein- and peptide-hormones are
proteolytically degraded in the stomach. But the idea of incretin
was born more than 110 years ago.
After the Banting & Best discovery of insulin in 1922 (17),
new attempts were taken to examine extracts of the duodenal
mucosa and their influence on blood glucose concentrations
(18–21). These results were also conflicting and inconclusive
(21), which in retrospect cannot surprise. But promising results
were nevertheless obtained by La Barre and Still, who in 1930
reported that they in the in vitro processing of duodenal extracts
had obtained two interesting fractions: One with crude secretin,
which in sophisticated cross-circulation experiments in dogs
stimulated the secretion from the exocrine pancreas, and another
which lowered blood glucose concentrations without effect on
the secretion of the exocrine pancreas (22). They also suggested
that the glucose-lowering effect was due to stimulated insulin
secretion (22). Then in 1932—as mentioned above (8)—La
Barre presented the name, incretin, together with suggestions
for treatment of diabetes mellitus with incretin (23). Strictly
speaking, the articulated idea of incretin-therapy for diabetes is
thus nearly a century old.
After La Barre’s hallmark contributions to the incretin story
(8, 21–23), the Austrian Hans Heller also prepared an extract
of the duodenal mucosa, which he in 1935 reported to lower
blood glucose concentrations—even after oral administration to
rabbits andman (24). Heller named the active factor in his extract
“duodenin.” His results, however, have not been followed up,
and the unspecific name duodenin was rapidly forgotten. Then,
synchronously with the onset of the Second World War, the
incretin-idea in general suffered an almost deadly blow from
the Chicago-school of gastrointestinal endocrinology (25–27).
The school was founded by Andrew Ivy, well known from the
discovery of cholecystokinin (CCK) in 1928 (28). After three
publications in rapid succession 1939–40 about acidification of
the duodenum in dogs at various blood glucose concentrations
(25–27), Ivy et al. concluded that the existence of an incretin is
unlikely. This opinion was neither challenged nor contradicted
during World War II and in the two first post-war decades. On
the contrary, the younger Ivy-pupil and -successor as spokesman
for American gastrointestinal endocrinology, Morton Grossman,
emphasized in a comprehensive high-impact review in 1950 the
scepticism against the incretin concept (29). But as time has
shown, Ivy and co-workers were wrong. They drew false-negative
conclusions of their experiments that in fact only showed that
secretin in dogs is without significant effect on insulin secretion.
Nevertheless, their publications paralyzed further ideas and
initiatives about incretin for a quarter of a century.
1960–2000: The year 1960 witnessed amajor breakthrough for
biomedicine and not least endocrinology. It virtually changed the
world and revitalized the interest in incretin. It was the invention
of the radioimmunoassay (RIA) by Berson and Yalow (30). The
RIA technique allowed for the first time in a fairly uncomplicated,
but accurate manner measurement of molecules present in pico-
to even femtomolar concentrations. A world of biologically active
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FIGURE 1 | Blood glucose, serum insulin and serum gastrin concentrations in
a normal subject after i.v. injection of synthetic human gastrin-17 (SHG), 250
ng kg−1 body weight (•), after i.v. injection of 25 g glucose (o), and after a
synchronous i.v. injection of both 250 ng kg−1 gastrin-17 and 25g glucose
(1). Data from Rehfeld & Stadil (44).
substances, including peptide hormones, circulates in plasma
in those concentrations. Therefore, RIA methods expanded
the dimensions of much biological and medical research. Not
least in basic and clinical endocrinology, because hormones are
defined by their circulation in blood. For good reasons, the
RIA technology was first applied to insulin (30). Therefore,
the method was immediately embraced by endocrinologists
and diabetologists studying pancreatic endocrine secretion and
diabetes mellitus. Only one year later, RIA measurement of
glucagon was launched by Unger et al. (31). And each year
during the following decades bursted with novel RIAs for
known and new pancreatic and gastrointestinal hormones
(32).
The possibility of direct and reliable measurements of insulin
in plasma soon reopened the incretin question. In 1964,
laboratories in London, UK [McIntyre et al. (33)] and Denver,
US [Elrick et al. (34)] independently showed that oral glucose
provokes a considerably larger insulin response than intravenous
glucose, even at similar blood glucose concentrations. Hence, the
gut harbors indeed insulinotropic hormonal factors. Or in other
words, the incretin mechanism exists. The reports of McIntyre
TABLE 1 | Twelve milestones in the first century of the history of the incretin
concept.
Name(s) Contribution Year References
1. Mering and
Minkowski
Pancreas as the site of diabetes 1889 (14)
2. Bayliss and
Starling
Discovery of secretin; the first
hormone
1902 (5)
3. Starling A gut hormone may stimulate the
endocrine pancreas
1905 (6)
4. La Barre and
Still
Evidence of an insulinotropic gut
hormone
1930 (22)
5. La Barre Coining the word incretin 1932 (8)
6. Yalow and
Berson
Invention of the radioimmunoassay 1960 (30)
7. McIntyre et al.
and Elrick et al.
Demonstration of a
glucose-dependent incretin
mechanism
1964 (33, 34)
8. Unger et al. Gut glucagon-like immunoreactivity 1966 (52)
9. Brown et al. Identification of GIP 1971 (46, 47)
10. Dupré and
Brown
GIP as an incretin 1973 (48)
11. Bell et al. Identification of GLP-1 1983 (55, 56)
12. Habener et al.
and Holst et al.
Truncated GLP-1 as an incretin 1987 (59, 60)
and Elrick et al. catalyzed new incretin studies in man, which
followed three lines.
One line focussed on in vivo development of methods for
quantitation of the glucose-induced incretin effect. Here, Perley
and Kipnis (35) showed that the incretin part of the insulin
response to oral glucose in man constituted more than half,
later confirmed to be probably two thirds or more of the insulin
response in healthy people, though smaller, with high age and
some gastrointestinal diseases (36, 37). Another line examined
the incretin effect of the then known troika of gastrointestinal
hormones (secretin, gastrin, and CCK) that could be obtained in
more or less pure forms in the mid-1960’s (38–43). These studies
were later reinvestigated with pure, synthetic peptides (44, 45).
The immediate results of the studies were less encouraging.
Oral glucose only elicited modest (gastrin and CCK) or no
increase (secretin) of endogenous secretion of the known gut
hormones. And the effect of isolated exogenous administration
in physiologically relevant doses of for instance gastrin only
stimulated insulin secretion to a minor extent [(44), see also
Figure 1]. A third line obtained more success with two later
identified gut hormones. In the early 1970’s, first in the laboratory
of Viktor Mutt in Stockholm, John Brown isolated GIP as an
inhibitor of gastric acid secretion (46, 47). In subsequent studies,
however, John Brown together with John Dupré showed that
GIP is a potent releaser of insulin during hyperglycemia, but
without effect in euglycemia (48). Thus, GIP was a glucose-
dependent incretin and was accordingly renamed “glucose-
dependent insulintropic polypeptide,” hence maintaining the
acronym with the new name [for reviews, see also Creutzfeldt
(49) and (50)]. The following quantitative studies of the incretin
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TABLE 2 | Examples of gastrointestinal neuroendocrine peptides that require
(further) examination of their incretin activity*.
Adrenomedullin
Apelin
Calcitonin Gene-Related Peptide (CGRP)
Cholecystokinin
Galanin
Gastrin
Gastrin-Releasing Peptide (GRP)
Ghrelin
Leptin
Motilin
Neurotensin
Neuropeptide Y (NPY)
Obestatin
Opioids
Pituitary Adenylate Cyclase Polypeptide (PACAP)
Peptide YY (PYY)
Vasoactive Intestinal Polypeptide (VIP)
Xenin
*Full examination requires studies of the isolated effect on basal and stimulated islet-
hormone secretion as well as studies of synergistic effects in combination with the other
gastrointestinal hormones (including GIP and GLP-1).
effect of GIP, however, suggested that GIP could not explain the
entire gut hormonal effect on insulin secretion after oral glucose.
Then in the mid- and late 1980’s, an additional gut
hormone with incretin-activity surfaced. The background for
the discovery was Unger and co-workers’ RIA-observations in
the 1960’s that the intestinal mucosa expressed some glucagon-
like immunoreactivity, which was different from the well-known
pancreatic glucagon peptide; hence the name “gut glucagon”
(51–53). Several laboratories in Europe and North America
subsequently tried to identify the bioactivity and structure of
gut glucagon peptides in the hope that one of them might
be a missing incretin [for review, see for instance (54)]. An
essential premise for success in this endeavor became the
cloning and sequencing of mammalian glucagon genes by
Graeme Bell and co-workers in 1983 (55, 56). The cDNA-
deduced proglucagon structure revealed unequivocally that
the prohormone in addition to the sequence of pancreatic
glucagon contained the sequences of two novel glucagon-like
peptides, which by Bell et al. were named GLP-1 and GLP-
2. Both GLP’s were expressed in the gut. GLP-1 as such
had a modest insulin-releasing activity (57), but purification
from gut extracts in the laboratories of Habener and Holst,
respectively, showed that GLP-1 was also synthetized in a
truncated (7-36) form with marked insulin-releasing effect (58–
61). Moreover, the truncated GLP-1 turned out also to inhibit
the secretion of pancreatic glucagon, which together with its
insulinotropic effect (59, 60) counteracts the hyperglycemia in
diabetes (62, 63). That GLP-1 moreover is a satiety signal that
facilitates weight loss and— as shown later—ameliorates the
cardiac function in diabetes has made GLP-1 an obvious drug
target for treatment of type 2 diabetes mellitus. Several GLP-
1-derived drugs are consequently now on the market and have
FIGURE 2 | Blood glucose, serum insulin and serum gastrin concentrations
during a protein-rich meal. The concentrations are indicated as mean ± SEM
(n = 8). Data from Rehfeld & Stadil (44).
been subject to comprehensive randomized and controlled trials
[for recent reports, see (64–68)]. So far, so good for GLP-
1 and GIP as incretins (2, 4). Essential milestones in first
century of the history of the incretin concept are pinpointed in
Table 1.
A PROBLEM
While nobody questions the insulinotropic activities of GIP and
GLP-1, it has become a problem that the present enthusiasm
for the two hormones and not least for GLP-1-derived drugs
has virtually suppressed supplementary ideas about additional
incretin activity of other gut hormones. The problem reflects an
old-fashioned and somewhat incorrect view on gastrointestinal
endocrinology, not least among GLP-1 enthusiasts. There are
different aspects to consider in this context.
First, the original definition of incretin is as stated “any
gut hormone, which under physiological circumstances
stimulates the secretion of pancreatic hormones.” Indeed,
several gastrointestinal hormones beyond GIP and GLP-1
stimulate insulin (see Table 2). For instance, gastrin accentuates
glucose-stimulated insulin secretion significantly (Figure 1), and
occasionally also glucagon secretion (37, 44). The effect of the
Frontiers in Endocrinology | www.frontiersin.org 4 July 2018 | Volume 9 | Article 387
Rehfeld The Incretin Concept
other hormones administered exogenously alone in the fasting
state may, however, be small and look trivial. But in combination
with for instance EGF (epidermal growth factor), GLP-1 and/or
during a meal (Figure 2), the effect may be significant as
discussed in detail for instance for gastrin and cholecystokinin
(37, 44, 69–73). Also the new gut hormone, xenin (74) displays
promising incretin activities (75–77). And acute administration
of PYY (1-36) as well as somatostatin inhibits insulin secretion.
Moreover, examination of gut hormone receptors on the
cell-membranes of pancreatic islet-cells is likely to show that
a considerable number of gastrointestinal hormones directly
influence the secretion of pancreatic hormones. For instance,
Reubi et al. found a fairly abundant expression of gastrin and
CCK receptors on human pancreatic islet cells (78).
Second, the old textbook-understanding of gastrointestinal
endocrinology has been a “one-hormone-one-target” without
functional overlap between the hormones: Gastrin regulated
gastric acid secretion; secretin pancreatic bicarbonate secretion;
CCK mainly gallbladder emptying; GIP only inhibition of gastric
secretion; motilin intestinal motility etc. This understanding
has in many ways turned out to be wrong and misleading.
Today we know that the digestive tract is the largest and
phylogenetically oldest endocrine organ in the body in which
30 different hormone genes are expressed and where the
prohormones are cellularly processed to more than 100 bioactive
peptides. Each hormone system has several targets both in and
outside the gastrointestinal tract. And different hormones may
simultaneously target the same organ and cells synergistically
with both stimulatory and inhibitory signals. Moreover, the same
enteroendocrine cell may express two or more different hormone
genes. And the enteroendocrine cells for a given hormone are
considerably more widespread in the gut than hitherto assumed.
For instance gastrin/CCK2-receptor agonists are expressed all the
way from the stomach to colorectal mucosa [for reviews, see for
instance (79, 80)]. Thus, the limitation of incretin activity to only
two peptides from the gastrointestinal tract may be somewhat
naïve and old-fashioned.
Third, the delineation of incretin activity in such close
relation to intake of glucose is also problematic. Of course,
the concentrations of glucose in circulation are relevant in
studies and discussions of insulin and glucagon secretion. But
oral intake of 50 or 75 g pure glucose as used in the oral
glucose tolerance tests is an unphysiological situation, which
cannot be used to exclude gut hormones as incretins under
normal physiological conditions. Several gut hormones respond
as mentioned poorly to pure glucose. But many respond vividly
to normal meals containing substantial amounts of protein,
fat, and complex carbohydrates without major changes in
blood glucose concentrations and under these circumstances
stimulate islet-hormone secretion in synergy with other gut
hormones (Figure 2). This in fact touches the fundamental role
of the enteroendocrine system: That meals—depending on their
composition—elicit variable polyphonies or rather symphonies
of gastrointestinal hormones playing together to ensure optimal
digestion and absorption of the food. This is the situation that
is relevant for definition of general endocrine activities of the
gut. Not only regarding incretin activity, but also other major
cross-hormonal activities such as gastrointestinal motility, the
inhibitory gastrone activities, satiety signaling etc., where several
different hormones interact for the purpose of ensuring optimal
nutrition.
CONCLUSION
Incretin and the use of incretin hormones in diabetes therapy
are old concepts with roots dating back to the second half
of the nineteenth century. The history of incretin reflects
a development characteristic for many lines of science with
alternating progress and retrogressions. The situation for incretin
today is based on decisive technical breakthroughs in disciplines
such as peptide purification and sequencing; radioimmunoassay
technology; cDNA cloning and sequencing; in vitro perfusion of
endocrine organs; and in vitro synthesis of polypeptide constructs
containing even three agonist epitopes. Probably, continued
incretin research will reveal further integration of GIP and
GLP-1 with additional gut peptides and provide a better and
more comprehensive physiological understanding of the incretin
concept. Such understanding may further the development of
biomedical diagnosis and incretin therapy. This development
is in fact already underway both in terms of GIP, GLP-1,
and/or glucagon dual and triple receptor agonists (81–84), and—
perhaps even more promising—dual or triple receptor agonists
that combine GLP-1 analogs with analogs of some of the other
gastrointestinal hormones (85–87).
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